image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 12.83
1.66 %
$ 15.3 B
Market Cap
-17.58
P/E
1. INTRINSIC VALUE

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.[ Read More ]

The intrinsic value of one VTRS stock under the base case scenario is HIDDEN Compared to the current market price of 12.8 USD, Viatris Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VTRS

image
FINANCIALS
15.4 B REVENUE
-5.14%
766 M OPERATING INCOME
-52.55%
54.7 M NET INCOME
-97.37%
2.8 B OPERATING CASH FLOW
-5.18%
-764 M INVESTING CASH FLOW
-50.25%
-2.3 B FINANCING CASH FLOW
40.64%
3.74 B REVENUE
-1.54%
226 M OPERATING INCOME
194.16%
94.8 M NET INCOME
129.04%
826 M OPERATING CASH FLOW
118.02%
1.75 B INVESTING CASH FLOW
365.11%
-1.64 B FINANCING CASH FLOW
-93.03%
Balance Sheet Decomposition Viatris Inc.
image
Current Assets 13 B
Cash & Short-Term Investments 1.18 B
Receivables 4.04 B
Other Current Assets 7.75 B
Non-Current Assets 34.7 B
Long-Term Investments 1.14 B
PP&E 3.01 B
Other Non-Current Assets 30.6 B
Current Liabilities 7.78 B
Accounts Payable 1.38 B
Short-Term Debt 2.02 B
Other Current Liabilities 4.38 B
Non-Current Liabilities 19.4 B
Long-Term Debt 16.4 B
Other Non-Current Liabilities 3.09 B
EFFICIENCY
Earnings Waterfall Viatris Inc.
image
Revenue 15.4 B
Cost Of Revenue 8.99 B
Gross Profit 6.44 B
Operating Expenses 5.97 B
Operating Income 766 M
Other Expenses 712 M
Net Income 54.7 M
RATIOS
41.74% GROSS MARGIN
41.74%
4.97% OPERATING MARGIN
4.97%
0.35% NET MARGIN
0.35%
0.27% ROE
0.27%
0.11% ROA
0.11%
0.54% ROIC
0.54%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Viatris Inc.
image
Net Income 54.7 M
Depreciation & Amortization 2.74 B
Capital Expenditures -474 M
Stock-Based Compensation 181 M
Change in Working Capital -711 M
Others 431 M
Free Cash Flow 2.33 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Viatris Inc.
image
Wall Street analysts predict an average 1-year price target for VTRS of $13.3 , with forecasts ranging from a low of $10 to a high of $15 .
VTRS Lowest Price Target Wall Street Target
10 USD -22.06%
VTRS Average Price Target Wall Street Target
13.3 USD 3.55%
VTRS Highest Price Target Wall Street Target
15 USD 16.91%
4. DIVIDEND ANALYSIS
1.03% DIVIDEND YIELD
0.12 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Viatris Inc.
image
Sold
0-3 MONTHS
7.4 M USD 2
3-6 MONTHS
4.52 M USD 2
6-9 MONTHS
3.94 M USD 5
9-12 MONTHS
228 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 days ago
Nov 11, 2024
Sell 347 K USD
Campbell Paul
See Remarks
- 26925
12.876 USD
1 year ago
Oct 26, 2023
Bought 171 USD
KORMAN HARRY
Director
+ 19
9.007 USD
2 years ago
Mar 16, 2022
Bought 2.49 K USD
KORMAN HARRY
Director
+ 238.76
10.421 USD
2 years ago
Mar 04, 2022
Bought 11.6 K USD
KORMAN HARRY
Director
+ 1150
10.079 USD
2 years ago
Dec 16, 2021
Bought 2.26 K USD
KORMAN HARRY
Director
+ 176.17
12.836 USD
3 years ago
Sep 16, 2021
Bought 2.24 K USD
KORMAN HARRY
Director
+ 162.44
13.811 USD
3 years ago
Jun 16, 2021
Bought 2.23 K USD
KORMAN HARRY
Director
+ 144.73
15.391 USD
3 years ago
Mar 09, 2021
Bought 4.86 K USD
KORMAN HARRY
Director
+ 349
13.939 USD
3 years ago
Feb 25, 2021
Bought 10.7 K USD
KORMAN HARRY
Director
+ 713
14.966 USD
3 years ago
Jan 15, 2021
Bought 14.2 K USD
KORMAN HARRY
Director
+ 837
16.993 USD
3 years ago
Dec 11, 2020
Bought 10.5 K USD
KORMAN HARRY
Director
+ 613
17.147 USD
2 months ago
Sep 12, 2024
Sell 1.63 M USD
Malik Rajiv
Director
- 139681
11.6563 USD
2 months ago
Sep 12, 2024
Sell 707 K USD
Malik Rajiv
Director
- 60319
11.7136 USD
2 months ago
Aug 28, 2024
Sell 595 K USD
Malik Rajiv
Director
- 50000
11.9015 USD
2 months ago
Aug 30, 2024
Sell 600 K USD
Malik Rajiv
Director
- 50000
12 USD
2 months ago
Aug 21, 2024
Sell 1.18 M USD
Malik Rajiv
Director
- 100000
11.7526 USD
2 months ago
Aug 22, 2024
Sell 1.17 M USD
Malik Rajiv
Director
- 100000
11.7263 USD
2 months ago
Aug 23, 2024
Sell 1.18 M USD
Malik Rajiv
Director
- 100000
11.751 USD
5 months ago
Jun 13, 2024
Sell 901 K USD
Malik Rajiv
Director
- 85660
10.5153 USD
5 months ago
Jun 14, 2024
Sell 2.69 M USD
Malik Rajiv
Director
- 264300
10.1789 USD
5 months ago
May 28, 2024
Sell 928 K USD
Roman Brian
Chief Legal Officer
- 89419
10.3829 USD
8 months ago
Mar 13, 2024
Sell 3.02 M USD
Mauro Anthony
See Remarks
- 250000
12.0948 USD
8 months ago
Mar 05, 2024
Sell 300 K USD
Campbell Paul
See Remarks
- 24353
12.33 USD
8 months ago
Mar 05, 2024
Sell 247 K USD
Lyons Dillon JoEllen
Director
- 20000
12.36 USD
8 months ago
Mar 04, 2024
Sell 223 K USD
Ni Xiangyang (Sean)
President, Greater China
- 17755
12.5394 USD
8 months ago
Mar 04, 2024
Sell 46.7 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3777
12.3582 USD
8 months ago
Feb 23, 2024
Sell 54 K USD
Cuneo Andrew
See Remarks
- 4000
13.5 USD
9 months ago
Feb 15, 2024
Sell 50 K USD
Cuneo Andrew
See Remarks
- 4000
12.5 USD
10 months ago
Jan 04, 2024
Sell 46 K USD
Cuneo Andrew
See Remarks
- 4000
11.5 USD
11 months ago
Dec 14, 2023
Sell 42 K USD
Cuneo Andrew
See Remarks
- 4000
10.5 USD
11 months ago
Nov 24, 2023
Sell 140 K USD
Ni Xiangyang (Sean)
President, Greater China
- 14937
9.3688 USD
1 year ago
Mar 06, 2023
Sell 34.9 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3148
11.0835 USD
1 year ago
Mar 03, 2023
Sell 34.6 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3093
11.1798 USD
1 year ago
Feb 28, 2023
Sell 58.9 K USD
Ni Xiangyang (Sean)
President, Greater China
- 5250
11.2178 USD
1 year ago
Nov 25, 2022
Sell 140 K USD
Ni Xiangyang (Sean)
President, Greater China
- 12800
10.9547 USD
2 years ago
Aug 17, 2022
Sell 99.9 K USD
van der Meer Mohr Pauline
director:
- 9440
10.5839 USD
2 years ago
May 27, 2022
Sell 106 K USD
Taddese Menassie
See Remarks
- 8813
12.0737 USD
2 years ago
Mar 15, 2022
Bought 26.7 K USD
CORNWELL W DON
director:
+ 2700
9.8968 USD
2 years ago
Mar 15, 2022
Bought 497 K USD
GOETTLER MICHAEL
Chief Executive Officer
+ 50352
9.866 USD
2 years ago
Mar 09, 2022
Sell 2.52 M USD
COURY ROBERT J
Executive Chairman
- 250000
10.0731 USD
7. News
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript) Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma at UBS, and welcome to UBS Global Healthcare Conference with us. seekingalpha.com - 1 day ago
Bargain Priced Viatris Reports Strong Q3 Earnings Results Bargain Priced Viatris Reports Strong Q3 Earnings Results seekingalpha.com - 1 week ago
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown Viatris Inc. VTRS reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results. benzinga.com - 1 week ago
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance VTRS Q3 earnings and sales beat estimates. New products perform well. zacks.com - 1 week ago
Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript Viatris Inc. (NASDAQ:VTRS ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Glen Santangelo - Jefferies Jason Gerberry - Bank of America Ethan Brown - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. seekingalpha.com - 1 week ago
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. zacks.com - 1 week ago
Xanax maker Viatris beats quarterly estimates on demand for new generic drugs Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.5% premarket. reuters.com - 1 week ago
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week. zacks.com - 1 week ago
Viatris Announces Third Quarter 2024 Dividend PITTSBURGH , Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. prnewswire.com - 1 week ago
Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. zacks.com - 1 week ago
Viatris Named to Forbes' World's Top Companies for Women 2024 List PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. prnewswire.com - 2 weeks ago
8. Profile Summary

Viatris Inc. VTRS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 15.3 B
Dividend Yield 1.03%
Description Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Contact 1000 Mylan Boulevard, Canonsburg, PA, 15317 https://www.viatris.com
IPO Date March 17, 1980
Employees 32000
Officers Dr. Jeffrey Nau MMS, Ph.D. President of Viatris Eye Care Division Mr. Ramkumar V. Rayapureddy Chief Information Officer Mr. Derek Glover Chief Quality Officer Mr. Brian S. Roman Chief Legal Officer Mr. Philippe Martin Chief R&D Officer Mr. Paul B. Campbell Chief Accounting Officer, Senior Vice President & Corporate Controller Ms. Theodora Mistras Chief Financial Officer Mr. Andrew Enrietti Chief People Officer Ms. Lara Ramsburg Chief Corporate Affairs Officer Mr. Menassie Taddese M.B.A. President of Emerging Markets